The company and law firm names shown above are generated automatically based on the text of the article. We are improving this feature as we continue to test and develop in beta. We welcome feedback, which you can provide using the feedback tab on the right of the page.
(Reuters) - Genetic testing company Natera Inc owes rival CareDx Inc $44.9 million for making false claims about the effectiveness of Natera's Prospera test for assessing the risk that a person's body will reject a kidney transplant, a Delaware jury said.
The jury decided Monday that Austin, Texas-based Natera owes $21.2 million in compensation for its false advertising and $23.7 million in punitive damages for competing unfairly with Brisbane, California-based CareDx.
The false advertising lawsuit by CareDx and a countersuit by Natera spun off from a patent dispute in which a Delaware judge last year invalidated the patents that CareDx accused Natera of infringing. (CareDx has appealed.)
The jury also found CareDx liable for false advertising based on a scientific paper that it claimed was independent but the company was involved in drafting, but rejected several other Natera false advertising claims. It did not determine how much CareDx owes in damages.
Natera stock was down nearly 16% on Tuesday following the verdict, while CareDx stock was up nearly 9%.
CareDx alleged in 2019 that Natera used the results of a flawed clinical trial to make misleading statements about the effectiveness of Prospera, which...
QUEENSLAND— A nurse in Australia has been formally reprimanded after admitting he submitted forged documents to Qantas (QF) in an attempt to secure a refund for a non-refundable airline ticket. Th...